Core Viewpoint - The Hong Kong pharmaceutical stocks are experiencing a strong performance, with notable gains in several companies [1] Company Performance - Sanofi Pharmaceutical-B (02257.HK) increased by 5.50% - Kangfang Biotech (09926.HK) rose by 5.23% - Genscript Biotech (01952.HK) saw a rise of 4.38% - Fudan Zhangjiang (01349.HK) grew by 4.21% [1]

Group 1 - The major shareholders of Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. are Yang Zongmeng and Wang Haibo, holding 7.18% and 5.41% of the total shares respectively before the reduction plan [1][2] - Yang Zongmeng planned to reduce his holdings by up to 4,270,800 shares, which is 0.41% of the total share capital, due to personal financial needs [1][2] - The reduction plan was disclosed on June 23, 2025, and the actual reduction took place from July 14 to July 16, 2025 [2][3] Group 2 - Yang Zongmeng reduced his holdings by 10,365,721 shares, representing 1.00% of the total share capital, with a total amount of approximately 92.79 million yuan [2][3] - Wang Haibo reduced his holdings by 4,270,722 shares, which is 0.41% of the total share capital, with a total amount of approximately 38.59 million yuan [3] - After the reductions, Yang Zongmeng's remaining shares are 64,009,773, which is 6.18% of the total share capital, while Wang Haibo's remaining shares are 51,828,605, which is 5.00% [3]

Group 1 - The Hang Seng Index fell by 0.08% on July 17, with southbound trading totaling HKD 134.72 billion, including HKD 68.29 billion in buying and HKD 66.43 billion in selling, resulting in a net inflow of HKD 1.85 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total turnover of HKD 49.60 billion, with net buying of HKD 0.19 billion, while Stock Connect (Shanghai) had a turnover of HKD 85.12 billion, with net buying of HKD 1.67 billion [1] - The most actively traded stock by southbound funds was Xiaomi Group-W, with a total turnover of HKD 64.88 billion, followed by Alibaba-W and Guotai Junan International with turnovers of HKD 52.03 billion and HKD 50.25 billion respectively [1] Group 2 - Among the stocks with net buying, Meituan-W led with a net inflow of HKD 6.06 billion, while China Construction Bank and Xiaomi Group-W followed with net inflows of HKD 5.91 billion and HKD 3.15 billion respectively [1][2] - The stock with the highest net selling was Pop Mart, with a net outflow of HKD 8.44 billion, and Tencent Holdings and Kangfang Biotech also experienced significant net selling of HKD 3.79 billion and HKD 0.76 billion respectively [1][2] - Meituan-W has seen continuous net buying for 9 days, with a total net inflow of HKD 72.14 billion during this period [2]

Core Insights - On July 17, 2025, Xiaomi Group-W (01810), Guotai Junan International (01788), and Alibaba-W (09988) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.809 billion, 3.754 billion, and 3.426 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Alibaba-W (09988), and Li Auto-W (02015) led the trading volume, with amounts of 2.680 billion, 1.777 billion, and 1.720 billion respectively [1] Southbound Stock Connect - Top Active Companies - Xiaomi Group-W (01810) had a trading amount of 3.809 billion with a net buying amount of +606 million [2] - Guotai Junan International (01788) recorded a trading amount of 3.754 billion with a net buying amount of +145 million [2] - Alibaba-W (09988) had a trading amount of 3.426 billion with a net buying amount of +30.17 million [2] - Other notable companies included Pop Mart (09992) with a trading amount of 2.162 billion and a net selling amount of -478 million, and Li Auto-W (02015) with a trading amount of 1.997 billion and a net selling amount of -204 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Xiaomi Group-W (01810) had a trading amount of 2.680 billion with a net selling amount of -290 million [2] - Alibaba-W (09988) recorded a trading amount of 1.777 billion with a net buying amount of +51.36 million [2] - Li Auto-W (02015) had a trading amount of 1.720 billion with a net buying amount of +29.1 million [2] - Other significant companies included Tencent Holdings (00700) with a trading amount of 1.627 billion and a net selling amount of -379 million, and Pop Mart (09992) with a trading amount of 1.316 billion and a net selling amount of -366 million [2]

关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本 的 7.18%；王海波先生持有公司股份 56,099,327 股，占公司总股本的 5.41%。上 述股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股 份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-024 上海复旦张江生物医药股份有限公司 集中竞价减持计划的实施结果情况 1、2025 年 6 月 23 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-018）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365 ...

Core Viewpoint - The Hong Kong innovative drug-themed ETFs have shown significant performance, with the top 10 ETFs all increasing by over 5%, indicating strong market interest in the innovative drug sector [1][2]. Group 1: ETF Performance - The Hang Seng Innovative Drug ETF (520500) led the gains with a 5.73% increase, reaching a value of 1.864 [2]. - Other notable ETFs include the Hong Kong Innovative Drug ETF with a 5.28% increase and the Hong Kong Stock Connect Innovative Drug ETF with a 5.26% increase [2]. - Among the top-performing stocks, Kangfang Biotech (09926.HK) and BeiGene (06160.HK) both rose over 10%, while Innovent Biologics (01801.HK) and CSPC Pharmaceutical Group (01093.HK) increased by over 3% [2]. Group 2: Market Trends - A total of 25 ETFs have increased by over 40% this year, with 24 of them being related to the Hong Kong biopharmaceutical theme, highlighting the sector's strong performance [3]. - The Hong Kong Innovative Drug Index has risen over 70% since the beginning of the year, significantly outperforming the Hang Seng Index, reflecting high market recognition of the innovative drug industry [4]. Group 3: Policy and Market Drivers - The continuous optimization of the policy environment has positively impacted market sentiment, with the National Healthcare Security Administration initiating adjustments to the 2025 National Medical Insurance Directory, which includes innovative drugs with high clinical value [5]. - The trend of Chinese innovative drugs going global has reached historic breakthroughs, indicating an increase in global competitiveness [5]. - Fund managers express optimism about the innovative drug sector, citing strong clinical data and ongoing product commercialization as key factors for future performance [6].

Summary of Key Points Core Viewpoint - Fudan Zhangjiang announced that shareholders Yang Zongmeng and Wang Haibo will reduce their holdings in the company through centralized bidding transactions, impacting the total shareholding structure of the company [1] Shareholder Reduction Details - Yang Zongmeng will reduce his holdings by 10.3657 million shares, which accounts for 1.00% of the company's total share capital, between July 14 and July 16, 2025 [1] - Wang Haibo will reduce his holdings by 4.2707 million shares, representing 0.41% of the company's total share capital, between July 14 and July 15, 2025, and has decided to terminate his reduction plan early [1] Post-Reduction Shareholding - After the reduction, Yang Zongmeng will hold 64.0098 million shares, which is 6.18% of the total shares [1] - After the reduction, Wang Haibo will hold 51.8286 million shares, which is 5.00% of the total shares [1]

Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceutical Group [2] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [2] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new products expected to be launched in the future [2] - The company has been recognized as a "High-tech Enterprise" in Shanghai since 1998 and has been involved in several national key technology projects [2] - Fudan Zhangjiang is listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, making it one of the few companies with A+H share listings [2] Financial Performance - As of March 31, 2025, Fudan Zhangjiang reported total revenue of 180 million yuan, a year-on-year increase of 21.85% [1] - The net profit attributable to shareholders was 2.6651 million yuan, reflecting a year-on-year growth of 13.53% [1] - The company's gross margin stood at 91.08%, with a debt-to-asset ratio of 8.82% [1] Stock Performance - As of July 17, the stock price of Fudan Zhangjiang was 4.4 HKD per share, marking a 14.29% increase with a trading volume of 373 million shares and a turnover of 1.744 billion HKD [1] - Over the past month, the stock has gained 14.31%, and year-to-date, it has increased by 57.99%, outperforming the Hang Seng Index, which rose by 22.22% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.45 times, with a median of 6.93 times [1] - Fudan Zhangjiang's P/E ratio is significantly higher at 92.37 times, ranking 73rd in the industry [1] - Comparatively, other companies in the sector have lower P/E ratios, such as Qianjing Pharmaceutical at 0.9 times and King’s Ray Biotechnology at 1.46 times [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock prices of several pharmaceutical companies listed on the Hong Kong Stock Exchange, indicating a positive trend in the sector [1] Group 2 - Company "三叶草生物" (Clover Biopharmaceuticals) experienced a stock price increase of 28.17% [1] - Company "复旦张江" (Fudan Zhangjiang) saw a rise of 22.86% in its stock price [1] - Company "康诺亚-B" (CanSino Biologics) reported an increase of 11.10% in its stock price [1] - Company "康方生物" (Kangfang Biologics) had a stock price increase of 11.03% [1]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market, particularly the healthcare sector, is experiencing a strong rally driven by the revaluation of innovative drug companies, with significant increases in stock prices and ETF performance [1][2]. - The CSI Hong Kong Innovative Drug Index rose by 4.23%, with notable gains from companies such as Fudan Zhangjiang (over 18% increase), Lepu Biopharma-B (over 10% increase), and Kangfang Biotech (over 9% increase) [1]. - The Hong Kong Innovative Drug 50 ETF (513780) saw a 3.57% increase, with a trading volume exceeding 200 million yuan within the first half hour of trading [1]. Group 2 - According to Jiao Yin International, the current innovative drug market in Hong Kong is driven by value re-evaluation, with attractive valuations compared to U.S. counterparts, as leading innovative drug companies have a forward 12-month price-to-sales ratio around 3 times, lower than the U.S. average of 4 times [2]. - Donghai Securities noted that the domestic innovative drug sector has seen increased activity this year, with high-value business development transactions and rising R&D investments, indicating a potential systematic recovery in the CXO and upstream life sciences sectors [2]. - Investment opportunities are suggested in various sub-sectors including CXO, innovative drugs, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2].